Snow Jennifer L, Kawut Steven M
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania School of Medicine, 844 West Gates Building, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Clin Chest Med. 2007 Mar;28(1):75-89, viii. doi: 10.1016/j.ccm.2006.11.005.
Recent discoveries in the disease pathophysiology of pulmonary arterial hypertension have been translated into effective therapies tested in clinical trials. The studies have focused on surrogate and intermediate end points, thought to reflect quantity and quality of life, respectively. The authors present the necessary requirements for establishing the reliability and validity of such end points before they may be used dependably. The authors also review the available data, strengths, and weaknesses of potential end points in pulmonary arterial hypertension.
肺动脉高压疾病病理生理学的最新发现已转化为在临床试验中进行测试的有效疗法。这些研究集中在替代终点和中间终点上，分别被认为反映生活质量的数量和质量。作者提出了在可靠使用这些终点之前建立其可靠性和有效性的必要要求。作者还回顾了肺动脉高压潜在终点的现有数据、优势和劣势。
